The beat on Q1 adjusted EPS and raised full-year guidance signal continued momentum in core therapeutic areas. Watch for FDA decisions on Skyrizi SC induction for Crohn's disease and Rinvoq for alopecia areata, which could further drive upside. Monitor Humira erosion trajectory and regulatory developments on trenibotulinumtoxinE.
Price Chart
Executive Summary
AbbVie reported Q1 2026 adjusted EPS of $2.65, above the prior company guidance range of $2.56-$2.60, and revenue of $15.002B (+12.4% YoY). The company raised full-year 2026 adjusted EPS guidance from $13.96-$14.16 to $14.08-$14.28, driven by strong growth in immunology (Skyrizi +30.9%, Rinvoq +23.3%) and neuroscience (+26.0%).
Key Financial Metrics
Key Facts
- Q1 2026 net revenue $15.002B, +12.4% YoY reported, +10.3% operational
- Q1 2026 adjusted diluted EPS $2.65, +7.7% YoY; GAAP EPS $0.39, -45.8% YoY
- Full-year 2026 adjusted diluted EPS guidance raised to $14.08-$14.28 from $13.96-$14.16
- Immunology revenue $7.290B (+16.4%), neuroscience $2.875B (+26.0%)
- Acquired IPR&D and milestones expense of $744M pre-tax ($0.41 per share drag)
Financial Impact
Revenue grew 12.4% to $15.002B, adjusted EPS up 7.7% to $2.65, full-year guidance raised by $0.12 at midpoint.
Risk Factors
- Humira revenue declining 38.6% YoY; Imbruvica down 24.7%
- FDA Complete Response Letter for trenibotulinumtoxinE (manufacturing issues)
- Reliance on Skyrizi and Rinvoq for growth; competition from biosimilars and new entrants
- Large non-cash charges (contingent consideration, amortization) depress GAAP earnings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001551152-26-000013 |
| Document: abbv-20260429.htm | 0001551152-26-000013 |
| Document: 0001551152-26-000013-index-headers.html | 0001551152-26-000013 |
| Document: 0001551152-26-000013-index.html | 0001551152-26-000013 |
| Document: 0001551152-26-000013.txt | 0001551152-26-000013 |
| 8-K Data (Synthetic) | 0001551152-26-000013 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | Court Ruling | $261.77 $264.48 | ▲ +1.04% | ▼ −0.62% | $259.94 (−0.70%) |
Sep 3, 2026 29d ago | 8-K | $260.21 $257.12 | ▼ −1.19% | ▼ −0.04% | $259.94 (−0.10%) |
Aug 5, 2026 8w ago | 8-K | $243.87 $250.82 | ▲ +2.85% | ▲ +1.64% | $259.94 (+6.59%) |
Aug 3, 2026 8w ago | Institutional Cluster | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $259.94 (+6.05%) |
Aug 3, 2026 8w ago | Court Ruling | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $259.94 (+6.05%) |
Jul 31, 2026 9w ago | 8-K | $250.94 $246.04 | ▼ −1.95% | ▼ −5.46% | $259.94 (+3.59%) |
Jul 27, 2026 9w ago | Court Ruling | $256.91 $250.94 | ▼ −2.32% | ▼ −3.40% | $259.94 (+1.18%) |
Jun 22, 2026 14w ago | 8-K | $230.01 $254.31 | ▲ +10.56% | ▲ +11.02% | $259.94 (+13.01%) |
May 18, 2026 19w ago | Court Ruling | $209.41 $213.12 | ▲ +1.77% | ▲ +0.15% | $259.94 (+24.13%) |
Apr 29, 2026 22w ago | 8-K | $203.89 $206.11 | ▲ +1.09% | ▼ −2.02% | $259.94 (+27.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access